#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Angiology is moving forward


Authors: doc. MUDr. Debora Karetová, CSc.
Authors‘ workplace: II. interní klinika − klinika kardiologie a angiologie 1. LF UK a VFN v Praze: U nemocnice, Praha 2
Published in: Čas. Lék. čes. 2016; 155: 171-174
Category: Review Article

Overview

Vascular medicine treats many diseases – ischemic syndromes of different arterial bed (with the specifics of their territorial function), venous and lymphatic diseases. A number of states in angiology are urgent, potentially life-threating. Examples include aneurysm rupture, acute limb ischemia, or deep vein thrombosis and pulmonary embolism.

On the other hand, chronic vascular disease (eg., peripheral arterial disease or chronic disease of superficial veins) require a differentiated approach according to the manifestation and the emphasis is given on prevention and treatment of disposing conditions.

The optimal care for patients bring the specialist in vascular medicine who is able to build a diagnostic and treatment work-up quickly. He works closely with vascular surgeons and interventional radiologists.

The article gives an overview of the major innovations in the field of angiology.

Keywords:
vascular medicine , disease of the carotid arteries , aortic aneurysm , thromboembolism, interdisciplinary approach


Sources

1. Townsend N, Nichols M, Scarborough P et al. Cardiovascular disease in Europe – epidemiological update 2015. Eur Heart J 2015; 36: 2696–2705.

2. Kuliha M, Roubec M, Prochazka V et al. Randomized clinical trial comparing neurological outcomes after carotid endarterectomy or stenting. Br J Surg 2015;102: 194–201.

3. Joergensen TM, Houlind K, Green A et al. Abdominal aortic diameter is increased in males with family history of abdominal aortic aneurysms: results from the Danish VIVA-trial. Eur J Vasc Endovasc Surg 2014; 48: 669–675.

4. Schermerhorn ML, Buck DB, O´Malley AJ et al. Long term outcomes of abdominal aortic aneurysm in the medicare population. N Engl J Med 2015; 373: 328–338.

5. IMPROVE Trial Investigators. Endovascular strategy or open repair for ruptured abdominal aortic aneurysm. Eur Heart J 2015; 36: 2061–2069.

6. Kolossvary E, Ferenci T, Kovats T et al. Trends in major lower limb amputation related to peripheral arterial disease in Hungary: a nationwide study (2004–2012). Eur J Vasc Endovasc Surg 2015; 50: 78–85.

7. Rosenfield K, Jaff MR, White CJ et al. Trial of a paclitaxel-coated ballon for femoropopliteal artery disease. N Engl J Med 2015; 373: 145–153.

8. Othieno R, Abu Affan M, Okpo E. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev 2007; CD003076.

9. Aujesky D, Roy PM, Verschuren F et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 2011; 378: 41.

10. Bauersachs R, Berkowitz SD, Brenner B et al.; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010 Dec 23; 363(26): 2499–510.

11. Büller HR, Prins MH et al.; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287.

12. Prins MH, Lensing AW, Bauersachs R et al.Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013 Sep 20; 11(1): 21.

13. Agnelli G, Buller HR, Cohen A et al.Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013 Aug 29; 369(9): 799–808.

14. Schulman S, Kearon C, Kakkar AK et al.; RE-COVER Study Group.Dabigatran versus warfarin in the treatment of acute venous thromboembolism. Circulation 2014 Feb 18; 129(7): 764–772.

15. Schulman S, Kakkar AK, Goldhaber SZ et al.; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.N Engl J Med 2009 Dec 10; 361(24): 2342–2352.

16. Pollack CV, Jr, Reilly PA, Eikelboom J et al. Idarucizumab for dabigatran reversal. N Engl J Med.2015; 373: 511–520.

Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental Hygienist
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#